Pub. Date : 2021 Apr
PMID : 32986876
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
1 | Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A-status in liver transplant recipients. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
2 | AIMS: Donor"s CYP3A-status (CYP3A5 genotype and CYP3A4 expression) can provide prognostic information regarding tacrolimus-metabolizing capacity of the liver graft and initial tacrolimus dosing for therapeutic blood concentrations in liver transplants. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
3 | AIMS: Donor"s CYP3A-status (CYP3A5 genotype and CYP3A4 expression) can provide prognostic information regarding tacrolimus-metabolizing capacity of the liver graft and initial tacrolimus dosing for therapeutic blood concentrations in liver transplants. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
4 | AIMS: Donor"s CYP3A-status (CYP3A5 genotype and CYP3A4 expression) can provide prognostic information regarding tacrolimus-metabolizing capacity of the liver graft and initial tacrolimus dosing for therapeutic blood concentrations in liver transplants. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
5 | The present work prospectively investigated whether CYP3A-status guided tacrolimus therapy has any potential clinical benefit for recipients in the early post-operative period. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
6 | METHODS: The contribution of preliminary assaying of donor CYP3A-status to the optimization of initial tacrolimus therapy and to the reduction of adverse events (acute rejection, infection, nephrotoxicity) was investigated in 112 liver transplant recipients (CYPtest group) comparing to 101 control patients on tacrolimus concentration guided therapy. | Tacrolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |